Tian-Li Wang

List of Publications by Year
in descending order

82	8,178	87888 38	69250 77
papers	citations	h-index	g-index

85	85	85	13805
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood, 2022, 139, 1939-1953.	1.4	15
2	Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC). Genes and Diseases, 2022, 9, 1408-1411.	3.4	5
3	The Origin of Ovarian Cancer Species and Precancerous Landscape. American Journal of Pathology, 2021, 191, 26-39.	3.8	102
4	IntAPT: integrated assembly of phenotype-specific transcripts from multiple RNA-seq profiles. Bioinformatics, 2021, 37, 650-658.	4.1	1
5	Genomeâ€wide mutation analysis in precancerous lesions of endometrial carcinoma. Journal of Pathology, 2021, 253, 119-128.	4.5	27
6	A Novel ZIP4-HDAC4-VEGFA Axis in High-Grade Serous Ovarian Cancer. Cancers, 2021, 13, 3821.	3.7	8
7	A novel human endometrial epithelial cell line for modeling gynecological diseases and for drug screening. Laboratory Investigation, 2021, 101, 1505-1512.	3.7	9
8	Mutation and methylation profiles of ectopic and eutopic endometrial tissues. Journal of Pathology, 2021, 255, 387-398.	4.5	8
9	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. IScience, 2021, 24, 103297.	4.1	12
10	Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer. Oncogene, 2021, 40, 6772-6785.	5.9	7
11	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. International Journal of Gynecological Pathology, 2020, 39, 26-35.	1.4	69
12	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. Cancer Research, 2020, 80, 4514-4526.	0.9	44
13	Methylomic Landscapes of Ovarian Cancer Precursor Lesions. Clinical Cancer Research, 2020, 26, 6310-6320.	7.0	15
14	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature Communications, 2020, 11, 2717.	12.8	45
15	Assessing aneuploidy with repetitive element sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 4858-4863.	7.1	50
16	Epithelial Cells in Endometriosis and Adenomyosis Upregulate STING Expression. Reproductive Sciences, 2020, 27, 1276-1284.	2.5	14
17	NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells. Aging, 2020, 12, 9275-9291.	3.1	6
18	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. EBioMedicine, 2019, 47, 184-194.	6.1	9

#	Article	IF	Citations
19	PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function. Cancer Immunology Research, 2019, 7, 257-268.	3.4	108
20	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. Clinical Cancer Research, 2019, 25, 5584-5594.	7.0	80
21	Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma. Cancer Cytopathology, 2019, 127, 192-201.	2.4	1
22	Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. Cell Reports, 2019, 27, 491-501.e6.	6.4	73
23	Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nature Communications, 2019, 10, 733.	12.8	39
24	Long Interspersed Nuclear Element 1 Retrotransposons Become Deregulated during the Development of Ovarian Cancer Precursor Lesions. American Journal of Pathology, 2019, 189, 513-520.	3.8	35
25	Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. Journal of Pathology, 2019, 248, 41-50.	4.5	84
26	T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers. Modern Pathology, 2019, 32, 576-584.	5.5	29
27	Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors. Molecular and Cellular Proteomics, 2019, 18, 448-460.	3.8	19
28	RNA-sequencing reveals immunotherapy targets in gynecological cancer.. Journal of Clinical Oncology, 2019, 37, 8-8.	1.6	1
29	BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget, 2019, 10, 6870-6878.	1.8	10
30	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. Oncogene, 2018, 37, 3778-3789.	5.9	22
31	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	12.6	1,872
32	CRNET: an efficient sampling approach to infer functional regulatory networks by integrating large-scale ChIP-seq and time-course RNA-seq data. Bioinformatics, 2018, 34, 1733-1740.	4.1	20
33	Independent development of endometrial epithelium and stroma within the same endometriosis. Journal of Pathology, 2018, 245, 265-269.	4.5	53
34	Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Reports, 2018, 22, 3393-3400.	6.4	77
35	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	12.4	178
36	SparseIso: a novel Bayesian approach to identify alternatively spliced isoforms from RNA-seq data. Bioinformatics, 2018, 34, 56-63.	4.1	7

#	Article	IF	Citations
37	Characterization of Primary Cilia in Normal Fallopian Tube Epithelium and Serous Tubal Intraepithelial Carcinoma. International Journal of Gynecological Cancer, 2018, 28, 1535-1544.	2.5	8
38	Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study. Cancer Prevention Research, 2018, 11, 697-706.	1.5	47
39	Reply to Haffner et al.: DNA hypomethylation renders tumors more immunogenic. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8583-E8584.	7.1	5
40	Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma. Gynecologic Oncology, 2018, 150, 426-431.	1.4	36
41	Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions. Clinical Cancer Research, 2018, 24, 6536-6547.	7.0	39
42	Human transposon insertion profiling: Analysis, visualization and identification of somatic LINE-1 insertions in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E733-E740.	7.1	86
43	Cancer-Associated Mutations in Endometriosis without Cancer. New England Journal of Medicine, 2017, 376, 1835-1848.	27.0	451
44	High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications, 2017, 8, 1093.	12.8	515
45	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. Human Pathology, 2017, 68, 87-91.	2.0	19
46	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. Gynecologic Oncology, 2017, 147, 85-91.	1.4	74
47	Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E10981-E10990.	7.1	217
48	CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. Modern Pathology, 2017, 30, 297-303.	5.5	48
49	Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach. Journal of Physical Education and Sports Management, 2017, 3, a001693.	1.2	12
50	Endometriosis: benign, malignant, or something in between?. Oncotarget, 2017, 8, 78263-78264.	1.8	27
51	The novel ZIP4 regulation and its role in ovarian cancer. Oncotarget, 2017, 8, 90090-90107.	1.8	27
52	Expression of Cell Competition Markers at the Interface between p53 Signature and Normal Epithelium in the Human Fallopian Tube. PLoS ONE, 2016, 11, e0156069.	2.5	1
53	Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1. Cancer Research, 2016, 76, 6351-6361.	0.9	61
54	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Modern Pathology, 2016, 29, 1254-1261.	5.5	72

#	Article	IF	Citations
55	Yes-associated protein impacts adherens junction assembly through regulating actin cytoskeleton organization. American Journal of Physiology - Renal Physiology, 2016, 311, G396-G411.	3.4	31
56	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. Journal of Biological Chemistry, 2016, 291, 9690-9699.	3.4	45
57	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. Nucleic Acids Research, 2016, 44, e65-e65.	14.5	15
58	Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell, 2015, 28, 82-96.	16.8	125
59	Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clinical Cancer Research, 2015, 21, 4652-4662.	7.0	48
60	Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. Gynecologic Oncology, 2015, 139, 338-344.	1.4	37
61	Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Modern Pathology, 2015, 28, 437-445.	5.5	16
62	The emerging roles of ARID1A in tumor suppression. Cancer Biology and Therapy, 2014, 15, 655-664.	3.4	200
63	Notch3 Interactome Analysis Identified WWP2 as a Negative Regulator of Notch3 Signaling in Ovarian Cancer. PLoS Genetics, 2014, 10, e1004751.	3.5	64
64	Roles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis. Journal of the National Cancer Institute, 2014, 106, .	6.3	105
65	Identification of the NAC1-Regulated Genes in Ovarian Cancer. American Journal of Pathology, 2014, 184, 133-140.	3.8	21
66	Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Human Pathology, 2014, 45, 691-700.	2.0	63
67	Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1490-9.	7.1	149
68	Detecting aberrant signal transduction pathways from high-throughput data using GIST algorithm. , 2012, , .		2
69	Defining NOTCH3 Target Genes in Ovarian Cancer. Cancer Research, 2012, 72, 2294-2303.	0.9	57
70	Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. American Journal of Pathology, 2012, 180, 1179-1188.	3.8	29
71	Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites. PLoS ONE, 2012, 7, e36054.	2.5	40
72	ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers. Cancer Research, 2011, 71, 6718-6727.	0.9	390

#	Article	IF	Citations
73	Molecular Genetic Markers in Female Reproductive Cancers. Journal of Oncology, 2010, 2010, 1-2.	1.3	1
74	Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma. Science, 2010, 330, 228-231.	12.6	1,090
75	Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin. American Journal of Pathology, 2010, 177, 1087-1094.	3.8	162
76	Jagged1 Expression Regulated by Notch3 and Wnt/Î²-catenin Signaling Pathways in Ovarian Cancer. Oncotarget, 2010, 1, 210-218.	1.8	86
77	Analyzing DNA Copy Number Changes Using Fused Margin Regression. , 2009, , .		0
78	Identification of Pbx1, a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer. Cancer Research, 2008, 68, 8852-8860.	0.9	66
79	Biomarker Identification by Knowledge-Driven Multi-Level ICA and Motif Analysis. , 2007, , .		5
80	Notch3 Gene Amplification in Ovarian Cancer. Cancer Research, 2006, 66, 6312-6318.	0.9	257
81	Prevalence of somatic alterations in the colorectal cancer cell genome. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3076-3080.	7.1	174
82	Targeting the Notch signaling pathway in cancer stem cells. , 0, , 128-138.		0